Prothena (PRTA) Competitors $6.40 -0.17 (-2.59%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.26 -0.14 (-2.17%) As of 07/11/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA vs. EWTX, MESO, TVTX, CVAC, CALT, GPCR, HROW, PAHC, ABCL, and NTLAShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Edgewise Therapeutics (EWTX), Mesoblast (MESO), Travere Therapeutics (TVTX), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Prothena vs. Its Competitors Edgewise Therapeutics Mesoblast Travere Therapeutics CureVac Calliditas Therapeutics AB (publ) Structure Therapeutics Harrow Phibro Animal Health AbCellera Biologics Intellia Therapeutics Edgewise Therapeutics (NASDAQ:EWTX) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends. Do analysts prefer EWTX or PRTA? Edgewise Therapeutics presently has a consensus target price of $40.00, indicating a potential upside of 189.02%. Prothena has a consensus target price of $31.50, indicating a potential upside of 392.19%. Given Prothena's higher possible upside, analysts plainly believe Prothena is more favorable than Edgewise Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Prothena 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do insiders and institutionals believe in EWTX or PRTA? 97.1% of Prothena shares are owned by institutional investors. 23.2% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 9.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, EWTX or PRTA? Edgewise Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Which has preferable valuation & earnings, EWTX or PRTA? Prothena has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$133.81M-$1.55-8.93Prothena$135.16M2.55-$122.31M-$2.08-3.08 Is EWTX or PRTA more profitable? Edgewise Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -79.94%. Prothena's return on equity of -21.61% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -30.95% -29.45% Prothena -79.94%-21.61%-19.32% Does the media prefer EWTX or PRTA? In the previous week, Edgewise Therapeutics had 3 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 1 mentions for Prothena. Edgewise Therapeutics' average media sentiment score of 0.73 beat Prothena's score of 0.51 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Edgewise Therapeutics Positive Prothena Positive SummaryEdgewise Therapeutics beats Prothena on 8 of the 15 factors compared between the two stocks. Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$353.64M$2.99B$5.60B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-3.0820.5827.9620.25Price / Sales2.55292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book0.717.638.045.49Net Income-$122.31M-$55.05M$3.18B$250.27M7 Day Performance-1.08%8.39%3.63%4.75%1 Month Performance26.23%5.35%4.04%7.64%1 Year Performance-71.52%1.95%29.55%16.34% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena3.5614 of 5 stars$6.40-2.6%$31.50+392.2%-71.4%$353.64M$135.16M-3.08130EWTXEdgewise Therapeutics1.5135 of 5 stars$12.61-3.2%$40.00+217.2%-38.0%$1.37BN/A-8.1460MESOMesoblast2.3183 of 5 stars$10.53-1.4%$18.00+70.9%+48.9%$1.36B$5.90M0.0080TVTXTravere Therapeutics3.6254 of 5 stars$14.60-2.7%$32.14+120.2%+68.2%$1.33B$233.18M-5.20460CVACCureVac4.6825 of 5 stars$5.41-0.7%$6.83+26.3%+67.0%$1.22B$579.18M5.88880Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.6129 of 5 stars$18.73-8.0%$76.17+306.7%-55.5%$1.17BN/A-21.53136HROWHarrow2.1927 of 5 stars$31.36-1.2%$61.40+95.8%+47.1%$1.16B$199.61M-56.00180News CoverageAnalyst ForecastPAHCPhibro Animal Health4.0515 of 5 stars$29.90+6.8%$24.40-18.4%+76.0%$1.13B$1.02B38.331,940Gap UpHigh Trading VolumeABCLAbCellera Biologics2.4382 of 5 stars$4.03+6.1%$7.50+86.1%+28.1%$1.13B$28.83M-7.20500Analyst RevisionHigh Trading VolumeNTLAIntellia Therapeutics4.3816 of 5 stars$10.25-4.6%$33.37+225.5%-53.2%$1.11B$57.88M-1.96600 Related Companies and Tools Related Companies Edgewise Therapeutics Competitors Mesoblast Competitors Travere Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Structure Therapeutics Competitors Harrow Competitors Phibro Animal Health Competitors AbCellera Biologics Competitors Intellia Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTA) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRTA Stock Alerts